Publication:


abstract

Purpose: The purpose of this review article is to describe the recent data supporting the use of epidermal growth factor receptor (EGFR) receptor tyrosine kinase inhibitors (TKIs) in the first-line setting of EGFR mutation-positive non-small cell lung cancer (NSCLC). Summary: EGFR receptor TKIs were originally developed in unselected NSCLC patients and demonstrated modest clinical benefit compared to placebo. With the discovery of improved benefits in the approximately 16% of NSCLC patients with an EGFR mutation, trials in selected populations were undertaken, demonstrating comparable efficacy to standard chemotherapy with an improved toxicity profile. The most common toxicity is rash, sometimes requiring dose adjustment and discontinuation and the most serious toxicity is interstitial lung disease, which occurs in about 1% of patients treated with EGFR receptor TKIs and is fatal in 30% who develop this toxicity. CONCLUSION: The EGFR receptor TKIs are an effective therapy in EGFR-mutated NSCLC and are recommended as first-line therapy for those with advanced or metastatic disease.

Related Articles
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
J Clin Oncol. 2011
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G. J Clin Oncol. 2011 May 20; 29(15):2121-7. Epub 2011 Apr 11.
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations.
Ther Adv Med Oncol. 2010
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations.
Okamoto I, Mitsudomi T, Nakagawa K, Fukuoka M. Ther Adv Med Oncol. 2010 Sep; 2(5):301-7.
Review EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.
J Thorac Oncol. 2008
Review EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.
Fong T, Morgensztern D, Govindan R. J Thorac Oncol. 2008 Mar; 3(3):303-10.
The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement.
Curr Oncol. 2009
The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement.
Ellis PM, Morzycki W, Melosky B, Butts C, Hirsh V, Krasnoshtein F, Murray N, Shepherd FA, Soulieres D, Tsao MS, et al. Curr Oncol. 2009 Jan; 16(1):27-48.
Review Gefitinib therapy for non-small cell lung cancer.
Curr Treat Options Oncol. 2005
Review Gefitinib therapy for non-small cell lung cancer.
Birnbaum A, Ready N. Curr Treat Options Oncol. 2005 Jan; 6(1):75-81.